EP0354777A2 - Dérivés du 3-(4-pipéridine)-5-(2-sulfonylaminoéthyl)-indole - Google Patents

Dérivés du 3-(4-pipéridine)-5-(2-sulfonylaminoéthyl)-indole Download PDF

Info

Publication number
EP0354777A2
EP0354777A2 EP89308083A EP89308083A EP0354777A2 EP 0354777 A2 EP0354777 A2 EP 0354777A2 EP 89308083 A EP89308083 A EP 89308083A EP 89308083 A EP89308083 A EP 89308083A EP 0354777 A2 EP0354777 A2 EP 0354777A2
Authority
EP
European Patent Office
Prior art keywords
formula
compound
compounds
process according
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP89308083A
Other languages
German (de)
English (en)
Other versions
EP0354777A3 (fr
EP0354777B1 (fr
Inventor
Ian Harold Coates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to AT89308083T priority Critical patent/ATE92485T1/de
Publication of EP0354777A2 publication Critical patent/EP0354777A2/fr
Publication of EP0354777A3 publication Critical patent/EP0354777A3/fr
Application granted granted Critical
Publication of EP0354777B1 publication Critical patent/EP0354777B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • This invention relates to indole derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their medical use, in particular to compounds and compositions of use in the treatment of migraine.
  • migraine may be associated with excessive dilatation of the cranial vasculature and known treatments for migraine include the administration of compounds having vasoconstrictor properties such as ergotamine.
  • ergotamine is a non-selective vasoconstrictor which constricts blood vessels throughout the body and has undesirable and potentially dangerous side effects.
  • Migraine may also be treated by administering an analgesic usually in combination with an antiemetic but such treatments are of limited value.
  • indole derivatives which are selective 5HT1-like receptor agonists and which exhibit selective vasoconstrictor activity have been described in the art as useful in the treatment of migraine.
  • R1 represents a C1 ⁇ 6 alkyl group
  • R2 represents a hydrogen atom or a C1 ⁇ 6alkyl group
  • R3 represents a hydrogen atom or a C1 ⁇ 3 alkyl group
  • pharmaceutically acceptable salts or solvates e.g. hydrates
  • a C1 ⁇ 6alkyl group may be a straight chain or a branched chain alkyl group, preferably a C1 ⁇ 3alkyl group such as methyl or ethyl.
  • R1 preferably represents a C1 ⁇ 3 alkyl group such as methyl.
  • R2 in the compounds of formula (I) preferably represents a hydrogen atom.
  • R3 in the compounds of formula (I) preferably represents a C1 ⁇ 3 alkyl group such as methyl.
  • a preferred compound according to the invention is : N-[2-[3-(1-Methyl-4-piperidinyl)-1 H -indol-5-yl]ethyl]­methanesulphonamide and its pharmaceutically acceptable salts and solvates.
  • Suitable pharmaceutically acceptable salts are those conventionally known in the art.
  • Examples of pharmaceutically acceptable salts include acid addition salts formed with inorganic acids, such as hydrochlorides, hydrobromides, phosphates and sulphates, and with organic acids, for example tartrates, maleates, fumarates, succinates and sulphonates.
  • Other salts which are not pharmaceutically acceptable may be useful in the preparation of compounds of formula (I) and these form a further part of the invention.
  • the invention embraces all optical isomers of the compounds of formula (I) and their mixtures, including racemic mixtures thereof.
  • the compounds of the invention show an enhanced bioavailability index in animals.
  • Compounds of the invention are useful in treating conditions associated with cephalic pain.
  • the compounds are useful in the treatment of migraine, cluster headache, chronic paroxysmal hemicrania and headache associated with vascular disorders and in alleviating the symptoms associated therewith.
  • the invention also provides a pharmaceutical composition which comprises at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate (e.g. hydrate) thereof and formulated for administration by any convenient route.
  • a pharmaceutical composition which comprises at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate (e.g. hydrate) thereof and formulated for administration by any convenient route.
  • Such compositions are preferably in a form adapted for use in medicine, in particular human medicine, and can conveniently be formulated in conventional manner using one or more pharmaceutically acceptable carriers or excipients.
  • a compound of formula (I) or a salt or solvate thereof for use in therapy, in particular in human medicine. It will be appreciated that use in therapy embraces but is not necessarily limited to use of a compound of formula (I) or a salt or solvate thereof as an active therapeutic substance.
  • a compound of formula (I) in the preparation of a medicament for use in the treatment of conditions associated with cephalic pain in particular migraine, cluster headache, chronic paroxysmal hemicrania and headache associated with vascular disorders.
  • a method for the treatment of a mammal comprising administration of an effective amount of a compound of formula (I) or salt or solvate thereof in particular in the treatment of conditions associated with cephalic pain and in alleviating the symptoms associated therewith.
  • the active ingredient may conveniently be presented in unit dose form.
  • a convenient unit dose formulation contains the active ingredient compound in an amount of from 0.1mg to 200mg.
  • the compounds according to the invention may for example be formulated for oral, sub-lingual, buccal, parenteral, rectal or intranasal administration or in a form suitable for administration by inhalation or insufflation (either through the mouth or nose).
  • the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate).
  • binding agents e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g. lactose, microcrystalline cellulose or calcium phosphate
  • lubricants e.g. magnesium stearate, talc or silica
  • disintegrants e.g. potato starch or sodium starch glycollate
  • Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters or ethyl alcohol); and preservatives (e.g. methyl or propyl- p -hydroxybenzoates or sorbic acid).
  • suspending agents e.g. sorbitol syrup, methyl cellulose or hydrogenated edible fats
  • emulsifying agents e.g. lecithin or acacia
  • non-aqueous vehicles e.g. almond oil, oily esters or ethyl alcohol
  • preservatives e
  • compositions may take the form of tablets or lozenges formulated in conventional manner.
  • the compounds of the invention may be formulated for parenteral administration by injection, conveniently intravenous or subcutaneous injection, for example by bolus injection or continuous intravenous infusion.
  • Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose containers, with an added preservative.
  • compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
  • the compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glyceride.
  • Tablets for sub-lingual administration may be formulated in a similar manner to those for oral administration.
  • the compounds of the invention may be used, for example, as a liquid spray or powder or in the form of drops.
  • the compounds according to the invention are conveniently delivered in the form of an aerosol spray presentation from pressurised packs or a nebuliser, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
  • the precise dose administered will depend on the age and condition of the patient, the particular compound used and the frequency and route of administration.
  • the compound may be administered in single or divided doses and may be administered one or more times, for example 1 to 4 times per day.
  • a proposed dose of the compounds of the invention for oral, sub­lingual, parenteral, buccal, rectal or intranasal administration to man (of approximately 70kg bodyweight) for the treatment of migraine is 0.1 to 200mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day.
  • a unit dose will preferably contain from 10 to 200 mg of the active ingredient.
  • a unit dose for parenteral administration will preferably contain 0.2 to 15 mg of the active ingredient.
  • Aerosol formulations are preferably arranged so that each metered dose or 'puff' delivered from a pressurised aerosol contains 0.2 mg to 2 mg of a compound of the invention, and capsules and cartridges delivered from an insufflator or an inhaler, contain 0.2 mg to 20 mg of a compound of the invention.
  • the overall daily dose by inhalation with an aerosol will be within the range 1 mg to 200 mg. Administration may be several times daily, for example from 2 to 8 times, giving for example 1, 2 or 3 doses each time.
  • Dosages of the compounds of the invention for rectal, sub-lingual or intranasal administration are similar to those for oral administration.
  • the compounds of the invention may, if desired, be administered in combination with one or more other therapeutic agents, such as analgesics, anti-inflammatory agents and anti-nauseants, and formulated for administration by any convenient route in conventional manner. Appropriate doses will be readily appreciated by those skilled in the art.
  • compounds of formula (I) and pharmaceutically acceptable salts and solvates may be prepared by methods known in the art for the preparation of analogous compounds such as the general methods outlined below.
  • R1, R2 and R3 are as defined for formula (I) unless otherwise specified.
  • compounds of formula (I) may be prepared by reduction of the corresponding compounds of formula (II).
  • the compounds of formula (II) are themselves novel compounds and form a further part of the invention.
  • the compounds of formula (II) have also been found to be selective 5HT1-like receptor agonists and potent and selective vasoconstrictors.
  • the reduction process may conveniently be carried out in the presence of hydrogen and a metal catalyst, such as palladium, Raney nickel, platinum, platinum oxide or rhodium which may be supported, for example, on charcoal.
  • a metal catalyst such as palladium, Raney nickel, platinum, platinum oxide or rhodium which may be supported, for example, on charcoal.
  • a homogenous catalyst such as tris(triphenylphosphine) rhodium chloride may be used.
  • the reduction may be carried out in a solvent such as an alcohol e.g. methanol or ethanol, an ether e.g. dioxan, an ester e.g. ethyl acetate or an amide e.g. dimethylformamide and conveniently at a temperature of from -10 to +50°C.
  • the compounds of formula (II) may be prepared by condensing a compound of formula (III): or a protected or activated derivative thereof, with a piperidone of formula (IV): or a salt or protected derivative thereof.
  • the condensation reaction may be effected in a suitable reaction medium in the presence of an acid or a base, conveniently at a temperature of 25 to 120°C.
  • Acids which may be employed in the above process include organic and inorganic acids such as sulphonic acids (e.g. p-toluenesulphonic acid), carboxylic acids (e.g. acetic acid) and preferably strong inorganic acids such as polyphosphoric acid, sulphuric acid and hydrochloric acid.
  • Suitable solvents for the reaction include inert solvents such as ethers (e.g. tetrahydrofuran or dioxan), alcohols (e.g. ethanol) and chlorinated hydrocarbons (e.g. chloroform or carbon tetrachloride). In some cases the acid may also act as the reaction solvent.
  • Bases which may be employed in the above process include alkali metal hydroxides (eg. potassium hydroxide), alkali metal alkoxides (e.g. sodium or potassium methoxide, ethoxide or t - butoxide), alkali metal hydrides (e.g. sodium hydride) and alkali metal amides (e.g. sodamide).
  • Suitable solvents for the reaction include alcohols (e.g. methanol or ethanol), ethers (e.g. tetrahydrofuran or dioxan) and dimethylsulphoxide.
  • a compound of formula (I) may be prepared by reacting a compound of formula (V): or a salt thereof (for example, an organic or inorganic acid addition salt such as the hydrochloride, hydrobromide, maleate, sulphate or creatinine sulphate adduct) or a protected derivative such as an N-silyl derivative thereof with a reagent serving to introduce the group R1SO2.
  • a salt thereof for example, an organic or inorganic acid addition salt such as the hydrochloride, hydrobromide, maleate, sulphate or creatinine sulphate adduct
  • a protected derivative such as an N-silyl derivative thereof
  • Suitable reagents which serve to introduce the group R1SO2- include sulphonylating agents corresponding to the acid R1SO3H such as acid halides (for example sulphonyl chlorides) or acid anhydrides (for example sulphonic anhydrides).
  • sulphonylating agents corresponding to the acid R1SO3H such as acid halides (for example sulphonyl chlorides) or acid anhydrides (for example sulphonic anhydrides).
  • the condensation process involving the sulphonylating agents may be effected in a suitable reaction medium which may be aqueous or non-aqueous and conveniently at a temperature of from -70 to +150°C.
  • a suitable reaction medium such as an amide (e.g. N,N′-dimethylformamide), an ether (e.g. tetrahydrofuran), a nitrile (e.g. acetonitrile), a haloalkane (e.g. dichloromethane) or mixtures thereof, optionally in the presence of a base such as pyridine or triethylamine or an inorganic base as calcium carbonate or sodium bicarbonate.
  • the organic base may also serve as a reaction solvent.
  • Compounds of formula (V) may be prepared by reduction of a corresponding compound having an appropriate reducible group as the 5-position substituent, such as -CH2CN using for example lithium aluminium hydride.
  • nitrile compounds are novel and constitute a further feature of the invention. These compounds may be prepared by any of the processes described hereinafter using starting materials in which the group R1SO2NHCH2 is replaced by a nitrile group.
  • a compound of formula (I) may be prepared by cyclisation of a compound of formula (VI)
  • the process is desirably carried out in the presence of polyphosphate ester in a reaction medium which may comprise one or more organic solvents, preferably halogenated hydrocarbons such as chloroform, dichloromethane, dichloroethane, dichlorodifluoromethane, or mixtures thereof.
  • a reaction medium which may comprise one or more organic solvents, preferably halogenated hydrocarbons such as chloroform, dichloromethane, dichloroethane, dichlorodifluoromethane, or mixtures thereof.
  • Polyphosphate ester is a mixture of esters which may be prepared from phosphorus pentoxide, diethylether and chloroform according to the method described in 'Reagents for Organic Synthesis', (Fieser and Fieser, John Wiley and Sons 1967).
  • the cyclisation may be carried out in aqueous or non-aqueous media, in the presence of an acid catalyst.
  • an aqueous medium such as an aqueous alcohol (e.g. methanol, ethanol or isopropanol) or an aqueous ether (e.g. dioxan or tetrahydrofuran) as well as mixtures of such solvents and the acid catalyst may be for example an inorganic acid such as concentrated hydrochloric, sulphuric or polyphosphoric acid. (In some cases the acid catalyst may also act as the reaction solvent).
  • an anhydrous reaction medium which may comprise one or more alcohols or ethers (e.g.
  • the acid catalyst will generally be a Lewis acid such as boron trifluoride, zinc chloride or magnesium chloride.
  • the cyclisation reaction may conveniently be carried out at temperatures of from 20 to 200°C preferably 50 to 125°C.
  • compounds of formula (I) may be prepared directly by the reaction of a compound of formula (VII): or a salt thereof, with a compound of formula (VIII) or a salt or protected derivative thereof (such as an acetal formed, for example, with an appropriate alkylorthoformate) using the appropriate conditions as described above. It will be appreciated that in this embodiment, a compound of formula (VI) is formed as an intermediate, and may be reacted in situ to form the desired compound of general formula (I).
  • Compounds of general formula (VI) may, if desired, be isolated as intermediates during the process for the preparation of compounds of formula (I) wherein a compound of formula (VII), or a salt or protected derivative thereof, is reacted with a compound of formula (VIII), or a salt or protected derivative thereof, in water or in a suitable solvent, such as an aqueous alcohol (e.g. methanol) at a temperature of, for example, 20 to 100°C. If an acetal or ketal of a compound of formula (VIII) is used, it Is necessary to carry out the reaction in the presence of an acid (for example, acetic or hydrochloric acid).
  • an acid for example, acetic or hydrochloric acid
  • a compound of formula (IX) may be reduced by catalytic hydrogenation using a catalyst such as palladium on charcoal to give an amine which may be diazotised using, for example nitrous acid and the product of this reaction may then be reduced using, for example, stannous chloride to give a compound of formula (VII).
  • a catalyst such as palladium on charcoal
  • amine which may be diazotised using, for example nitrous acid
  • the product of this reaction may then be reduced using, for example, stannous chloride to give a compound of formula (VII).
  • a compound of formula (I) may be prepared by reduction of a compound of formula (X)
  • the reduction may be effected using similar reaction conditions to those described for general process (A) above.
  • Compounds of formula (X) may be prepared by reacting a compound of formula (XI) (wherein X represents a leaving atom or group such as a halogen atom for example a bromine atom) with an alkene
  • the reaction will generally be effected in the presence of a palladium catalyst and a base.
  • the catalyst may be, for example, palladium on charcoal or a palladium salt.
  • Palladium salts which may be employed as catalysts include salts of organic acids such as acetates or salts of inorganic acids such as chlorides or bromides.
  • the base may be, for example, a tertiary nitrogen base such as triethylamine or tri-n-butylamine or an alkali metal carbonate such as sodium carbonate.
  • the reaction may optionally be carried out in the presence of a phosphine, for example a triarylphosphine such as triphenylphosphine or tri-o-tolylphosphine.
  • a phosphine should be present when the process is effected with a compound of formula (XI) wherein X represents a bromine atom.
  • General process (D) may be effected in the presence or absence of solvent.
  • An anhydrous or aqueous reaction medium comprising one or more solvents may be employed.
  • Suitable solvents include nitriles, for example, acetonitrile, alcohols, for example methanol, amides, for example dimethylformamide, N-methylpyrrolidone or hexamethylphosphoramide; and water.
  • the reaction may conveniently be carried out at a temperature of from 25 to 200°C, preferably 75 to 150°C.
  • a compound of formula (I) according to the invention may be converted into another compound of the invention using conventional procedures.
  • a compound of general formula (I) wherein one or more of R2 and R3 represent hydrogen atoms may be alkylated using conventional techniques.
  • the reaction may be effected using a suitable alkylating agent such as an alkyl halide, alkyl tosylate or dialkylsulphate.
  • a suitable alkylating agent such as an alkyl halide, alkyl tosylate or dialkylsulphate.
  • the alkylation reaction may conveniently be carried out in an inert organic solvent such as an amide (e.g dimethylformamide) or an ether (e.g. tetrahydrofuran) preferably in the presence of a base.
  • Suitable bases include, for example, alkali metal hydrides, such as sodium hydride, alkali metal carbonates, such as sodium carbonate or alkali metal alkoxides such as sodium or potassium methoxide, ethoxide or t -butoxide.
  • alkali metal hydrides such as sodium hydride
  • alkali metal carbonates such as sodium carbonate
  • alkali metal alkoxides such as sodium or potassium methoxide, ethoxide or t -butoxide.
  • the alkylation reaction is conveniently carried out at a temperature of from 25 to 100°C.
  • a compound of general formula (I) according to the invention, or a salt thereof may be prepared by subjecting a protected derivative of general formula (I) or a salt thereof to reaction to remove the protecting group or groups.
  • the protecting groups used in the preparation of compounds of formula (I) may be used in conventional manner. See for example 'Protective Groups in Organic Chemistry' Ed.J.F.W. McOmie (Plenum Press 1973) or 'Protective Groups in Organic Synthesis' by Theodora W Greene (John Wiley and Sons 1981).
  • the group NR3 may be protected for example by protonation or with a conventional amino protecting group.
  • groups may include for example aralkyl groups, such as benzyl, diphenylmethyl or triphenylmethyl groups; and acyl groups such as N-benzyloxycarbonyl or t-butoxycarbonyl.
  • the indole nitrogen may also be protected, for example by an aralkyl group such as benzyl or a trialkyl silyl derivative
  • an aralkyl group such as benzyl
  • a catalyst e.g. palladium on charcoal
  • an acyl group such as N-benzyloxycarbonyl may be removed by hydrolysis with, for example, hydrogen bromide in acetic acid or by reduction, for example by catalytic hydrogenation.
  • a compound of the invention for example as a salt, for example as an acid addition salt
  • this may be achieved by treating the free base of general formula (I) with an appropriate acid, preferably with an equivalent amount, or with creatinine sulphate in a suitable solvent (e.g. aqueous ethanol).
  • a suitable solvent e.g. aqueous ethanol
  • the general methods indicated above for the preparation of the compounds of the invention may also be used for the introduction of the desired groups at an intermediate stage in the preparation of the required compound. It should therefore be appreciated that in such multi-stage processes, the sequence of reactions should be chosen in order that the reaction conditions do not affect groups present in the molecule which are desired in the final product.
  • stage (ii) (1.00g) in ethanolic hydrogen chloride (200ml) was hydrogenated for 1h over pre-reduced 10% palladium on carbon (50% paste with water, 1.00g).
  • the active ingredient is sieved and blended with the anhydrous lactose and magnesium stearate.
  • the resultant mix is compressed into tablets using a Manesty F3 tablet machine fitted with 8.0mm concave punches.
  • mg/tablet Active ingredient 50 Magnesium Stearate BP 0.7 Microcrystalline Cellulose NF 90
  • the active ingredient is sieved and blended with the microcrystalline cellulose and magnesium stearate.
  • the resultant mix is compressed into tablets using a Manesty F3 tablet machine fitted with 8.0mm concave punches.
  • B WET GRANULATION mg/tablet Active ingredient 50.0 Lactose BP 153.5
  • the active ingredient is sieved through a suitable sieve and blended with lactose, starch and pregelatinised maize starch. Suitable volumes of purified water are added and the powders are granulated. After drying, the granules are screened and blended with the magnesium stearate. The granules are then compressed into tablets using suitable diameter punches.
  • Tablets of other strengths may be prepared by altering the ratio of active ingredient to lactose or the compression weight and using punches to suit.
  • the tablets may be film coated with suitable film-forming materials, such as hydroxypropyl methylcellulose, using standard techniques. Alternatively the tablets may be sugar coated, or enteric coated.
  • the active ingredient is sieved and blended with the excipients.
  • the mix is filled into size No.2 hard gelatin capsules using suitable machinery.
  • Other doses may be prepared by altering the fill weight and if necessary changing the capsule size to suit.
  • the hydroxypropylmethylcellulose is dispersed in hot water, cooled and then mixed with an aqueous solution containing the active ingredient and the other components of the formulation.
  • the resultant solution is adjusted to volume and mixed.
  • the syrup is clarified by filtration.
  • the aluminium monostearate is dispersed in about 90% of the fractionated coconut oil.
  • the resulting suspension is heated to 115°C while stirring and then cooled.
  • the sweetening agent, flavour and colour are added and the active ingredient is suitably dispersed.
  • the suspension is made up to volume with the remaining fractionated coconut oil and mixed.
  • SUB-LINGUAL TABLET mg/tablet Active Ingredient 50.00 Compressible Sugar NF 49.5 Magnesium Stearate BP 0.5 Compression Weight 100.0
  • the active ingredient is sieved through a suitable sieve, blended with the excipients and compressed using suitable punches. Tablets of other strengths may be prepared by altering either the ratio of active ingredient to excipients or the compression weight and using punches to suit.
  • a suspension of the active ingredient in molten Witepsol is prepared and filled, using suitable machinery, into 1g size suppository moulds.
  • INJECTION FOR INTRAVENOUS ADMINISTRATION mg/ml Sodium Chloride Intravenous 1.0 Infusion, BP, 0.9% w/v to 1 ml Batch Size 2500ml
  • the active ingredient is dissolved in a portion of the Sodium Chloride Intravenous Infusion, the solution made to volume with the Sodium Chloride Intravenous Infusion, and the solution thoroughly mixed.
  • the solution is filled into clear, Type 1, glass 10ml ampoules and sealed under a nitrogen headspace by fusion of the glass The ampoules are sterilised by autoclaving at 121°C for not less than 15 minutes.
  • the active ingredient is micronised in a fluid energy mill to a fine particle size range prior to blending with normal tabletting grade lactose in a high energy mixer.
  • the powder blend is filled into No. 3 hard gelatin capsules on a suitable encapsulating machine.
  • the contents of the cartridges are administered using a powder inhaler such as the Glaxo Rotahaler.
  • a powder inhaler such as the Glaxo Rotahaler.
  • Metered Dose Pressurised Aerosol Suspension Aerosol mg/metered dose Per can Active ingredient (micronised) 0.500 132.00mg Oleic Acid BP 0.050 13.2mg Trichlorofluoromethane BP 23.12 5.55g Dichlorodifluoromethane BP 61.25 14.70g
  • the active ingredient is micronised in a fluid energy mill to a fine particle size range.
  • the oleic acid is mixed with the trichloro­methane at a temperature of 10-15°C and the micronised drug is mixed into the solution with a high shear mixer.
  • the suspension is metered into aluminium aerosol cans and suitable metering valves, delivering 85mg of suspension are crimped onto the cans and the dichlorodifluoro­methane is pressure filled into the cans through the valves.
  • Nasal Spray % w/v Active Ingredient 10.0 Preservative as required Sodium Chloride BP Purified Water BP to 100 Shot Weight 100mg (equivalent to 10mg active ingredient)
  • the active ingredient, preservative and sodium chloride are dissolved in a portion of the water, the solution made to volume with the water and the solution thoroughly mixed.
  • the pH may be adjusted, using acid or alkali, to that of optimum stability and/or to facilitate solution of the active ingredient.
  • suitable buffer salts may be used.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP89308083A 1988-08-10 1989-08-09 Dérivés du 3-(4-pipéridine)-5-(2-sulfonylaminoéthyl)-indole Expired - Lifetime EP0354777B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT89308083T ATE92485T1 (de) 1988-08-10 1989-08-09 3-(4-piperidin)-5-(2-sulphonylaminoethyl)-indol derivate.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888819024A GB8819024D0 (en) 1988-08-10 1988-08-10 Chemical compounds
GB8819024 1988-08-10

Publications (3)

Publication Number Publication Date
EP0354777A2 true EP0354777A2 (fr) 1990-02-14
EP0354777A3 EP0354777A3 (fr) 1991-04-10
EP0354777B1 EP0354777B1 (fr) 1993-08-04

Family

ID=10641919

Family Applications (1)

Application Number Title Priority Date Filing Date
EP89308083A Expired - Lifetime EP0354777B1 (fr) 1988-08-10 1989-08-09 Dérivés du 3-(4-pipéridine)-5-(2-sulfonylaminoéthyl)-indole

Country Status (13)

Country Link
US (1) US5036078A (fr)
EP (1) EP0354777B1 (fr)
JP (1) JP2941309B2 (fr)
KR (1) KR900003151A (fr)
AT (1) ATE92485T1 (fr)
AU (1) AU3945589A (fr)
DE (1) DE68908040T2 (fr)
DK (1) DK391289A (fr)
FI (1) FI893751A (fr)
GB (1) GB8819024D0 (fr)
NO (1) NO893205L (fr)
PT (1) PT91417B (fr)
ZA (1) ZA896067B (fr)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018897A1 (fr) * 1990-06-07 1991-12-12 The Wellcome Foundation Limited Composes heterocycliques therapeutiques
WO1993024116A1 (fr) 1992-05-28 1993-12-09 Glaxo Canada Inc. Compositions pharmaceutiques comprenant des agonistes des recepteurs 5-ht1 et des stimulateurs d'absorption
WO1995009166A1 (fr) * 1993-09-29 1995-04-06 Glaxo Group Limited Procede de preparation du n-methyl-3-(1-methyl-4-piperidinyl)-14-indole-5-ethanesulfonamide
US5498626A (en) * 1992-04-10 1996-03-12 Pfizer Inc. Acylaminoindole derivatives as 5-ht1 agonists
US5594014A (en) * 1992-03-05 1997-01-14 Pfizer Inc Indole derivatives as 5-HT1 agonists
US5639779A (en) * 1992-04-10 1997-06-17 Pfizer Inc. Indole derivatives as 5-HT1-like agonists
US5639752A (en) * 1991-11-25 1997-06-17 Pfizer Inc Indole derivatives
US5747501A (en) * 1992-04-07 1998-05-05 Pfizer, Inc. Indole derivatives
CN1039322C (zh) * 1990-10-15 1998-07-29 美国辉瑞有限公司 吲哚衍生物的制备方法
WO1998042344A1 (fr) * 1997-03-24 1998-10-01 R. P. Scherer Limited Composition pharmaceutique
US5886008A (en) * 1992-11-02 1999-03-23 Pfizer Inc. 5-arylindole derivatives
US5973156A (en) * 1995-11-17 1999-10-26 Merck Sharp & Dome Ltd. Piperidine and tetrahydropyridine derivatives
US6380233B1 (en) 1992-04-07 2002-04-30 Pfizer Inc Indole derivatives as 5-HT1 agonists
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US7297711B2 (en) 2002-06-21 2007-11-20 Suven Life Sciences Limited Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
US7649097B2 (en) 2002-06-21 2010-01-19 Suven Life Sciences Limited Tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
US7718690B2 (en) 2002-11-28 2010-05-18 Venkata Satya Nirogi Ramakrishna N-arylsulfonyl-3-aminoalkoxyindoles
US7875605B2 (en) 2002-11-28 2011-01-25 Suven Life Sciences Limited N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT88255B (pt) * 1987-08-13 1995-03-01 Glaxo Group Ltd Processo para a preparacao de derivados do indole
DK733788A (da) * 1988-01-14 1989-07-15 Fujisawa Pharmaceutical Co Indolylpiperidinderivater og fremgangsmaade til fremstilling deraf
DK152090D0 (da) * 1990-06-22 1990-06-22 Lundbaek A S H Piperidylsubstituerede indolderivater
US5643784A (en) * 1990-12-04 1997-07-01 H, Lundbeck A/S Indan derivatives
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
JPH06162097A (ja) * 1992-11-16 1994-06-10 Mitsutoyo Corp データベースの検索条件設定方式
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
TR199700993T1 (xx) * 1995-03-20 1998-03-21 Eli Lilly And Company 5-ikameli-3-(1,2,3,6-tetrahidropridin-4-il)- ve 3-(piperidin-4-il)-1H-indoller: yeni 5-HT1F agonistler.
JP4571507B2 (ja) 2002-12-18 2010-10-27 スベン ライフ サイエンシズ リミティド セロトニン受容体親和性を有する四環系３−置換インドール
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2362628A1 (fr) * 1976-08-26 1978-03-24 Roussel Uclaf Nouveaux derives du piperidyl-indole et leurs sels, procede de preparation et application a titre de medicaments
GB2081717A (en) * 1980-08-12 1982-02-24 Glaxo Group Ltd Hereocyclic compounds
EP0200322A1 (fr) * 1985-04-10 1986-11-05 H. Lundbeck A/S Composés hétérocycliques
GB2186874A (en) * 1986-01-08 1987-08-26 Glaxo Group Ltd Pharmaceutically active 5-acylaminoalkyl-3-aminoalkyl-1H-indoles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2421899A1 (fr) * 1978-01-16 1979-11-02 Roussel Uclaf Nouveaux derives du tetrahydropyridinyl-indole et leurs sels, le procede de preparation et l'application a titre de medicaments de ces nouveaux produits
FR2533924A1 (fr) * 1982-10-05 1984-04-06 Roussel Uclaf Nouveaux derives du 4-(1h-indol-3-yl)a-methyl piperidine-1-ethanol, leurs sels, le procede de preparation, l'application a titre de medicaments et les compositions les renfermant
DE3419935A1 (de) * 1984-05-28 1985-11-28 Merck Patent Gmbh, 6100 Darmstadt Verwendung von hydroxyindolderivaten bei der senkung des blutdrucks
DE3430284A1 (de) * 1984-08-17 1986-02-27 Troponwerke GmbH & Co KG, 5000 Köln Neue tryptamin-derivate, ein verfahren zu ihrer herstellung und ihre verwendung
US4548939A (en) * 1984-10-01 1985-10-22 Janssen Pharmaceutica N. V. 1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
PT88255B (pt) * 1987-08-13 1995-03-01 Glaxo Group Ltd Processo para a preparacao de derivados do indole

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2362628A1 (fr) * 1976-08-26 1978-03-24 Roussel Uclaf Nouveaux derives du piperidyl-indole et leurs sels, procede de preparation et application a titre de medicaments
GB2081717A (en) * 1980-08-12 1982-02-24 Glaxo Group Ltd Hereocyclic compounds
EP0200322A1 (fr) * 1985-04-10 1986-11-05 H. Lundbeck A/S Composés hétérocycliques
GB2186874A (en) * 1986-01-08 1987-08-26 Glaxo Group Ltd Pharmaceutically active 5-acylaminoalkyl-3-aminoalkyl-1H-indoles

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018897A1 (fr) * 1990-06-07 1991-12-12 The Wellcome Foundation Limited Composes heterocycliques therapeutiques
AU646871B2 (en) * 1990-06-07 1994-03-10 Astrazeneca Uk Limited Therapeutic heterocyclic compounds
EP0636623A1 (fr) * 1990-06-07 1995-02-01 The Wellcome Foundation Limited Dérivés d'indole comme 5-HT1-like agonistes
US5399574A (en) * 1990-06-07 1995-03-21 Burroughs Wellcome Co. Indolyl tetrahydropyridines for treating migraine
US5466699A (en) * 1990-06-07 1995-11-14 Burroughs Wellcome Co. Indolyl compounds for treating migraine
US5863935A (en) * 1990-06-07 1999-01-26 Zeneca Limited Therapeutic heterocyclic compounds
CN1039322C (zh) * 1990-10-15 1998-07-29 美国辉瑞有限公司 吲哚衍生物的制备方法
CN1045294C (zh) * 1991-11-25 1999-09-29 美国辉瑞有限公司 吲哚衍生物的制备方法
US5639752A (en) * 1991-11-25 1997-06-17 Pfizer Inc Indole derivatives
US5717102A (en) * 1992-03-05 1998-02-10 Pfizer Inc. Indole derivatives as 5-HT1 agonists
US5594014A (en) * 1992-03-05 1997-01-14 Pfizer Inc Indole derivatives as 5-HT1 agonists
US6387937B1 (en) 1992-04-07 2002-05-14 Pfizer Inc. Indole derivatives
US6436957B1 (en) 1992-04-07 2002-08-20 Pfizer Inc. Indole derivatives as 5-HT1 agonists
US5747501A (en) * 1992-04-07 1998-05-05 Pfizer, Inc. Indole derivatives
US6465500B1 (en) 1992-04-07 2002-10-15 Pfizer Inc. Indole derivatives as 5-HT1 agonists
US6410739B1 (en) 1992-04-07 2002-06-25 Pfizer Inc Indole derivatives as 5-HT1 agonists
US6387941B1 (en) 1992-04-07 2002-05-14 Pfizer Inc. Indole derivatives as 5-HT1 agonists
US6380233B1 (en) 1992-04-07 2002-04-30 Pfizer Inc Indole derivatives as 5-HT1 agonists
US5498626A (en) * 1992-04-10 1996-03-12 Pfizer Inc. Acylaminoindole derivatives as 5-ht1 agonists
US5639779A (en) * 1992-04-10 1997-06-17 Pfizer Inc. Indole derivatives as 5-HT1-like agonists
WO1993024116A1 (fr) 1992-05-28 1993-12-09 Glaxo Canada Inc. Compositions pharmaceutiques comprenant des agonistes des recepteurs 5-ht1 et des stimulateurs d'absorption
US5886008A (en) * 1992-11-02 1999-03-23 Pfizer Inc. 5-arylindole derivatives
US5659040A (en) * 1993-09-29 1997-08-19 Glaxo Group Limited Process for the preparation of N-methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulphonamide
WO1995009166A1 (fr) * 1993-09-29 1995-04-06 Glaxo Group Limited Procede de preparation du n-methyl-3-(1-methyl-4-piperidinyl)-14-indole-5-ethanesulfonamide
US5973156A (en) * 1995-11-17 1999-10-26 Merck Sharp & Dome Ltd. Piperidine and tetrahydropyridine derivatives
WO1998042344A1 (fr) * 1997-03-24 1998-10-01 R. P. Scherer Limited Composition pharmaceutique
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US7297711B2 (en) 2002-06-21 2007-11-20 Suven Life Sciences Limited Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
US7649097B2 (en) 2002-06-21 2010-01-19 Suven Life Sciences Limited Tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
US7718690B2 (en) 2002-11-28 2010-05-18 Venkata Satya Nirogi Ramakrishna N-arylsulfonyl-3-aminoalkoxyindoles
US7875605B2 (en) 2002-11-28 2011-01-25 Suven Life Sciences Limited N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them

Also Published As

Publication number Publication date
JPH0291068A (ja) 1990-03-30
US5036078A (en) 1991-07-30
PT91417B (pt) 1995-05-04
JP2941309B2 (ja) 1999-08-25
ZA896067B (en) 1990-06-27
DK391289D0 (da) 1989-08-09
NO893205L (no) 1990-02-12
DE68908040D1 (de) 1993-09-09
PT91417A (pt) 1990-03-08
DE68908040T2 (de) 1993-11-18
AU3945589A (en) 1990-02-15
GB8819024D0 (en) 1988-09-14
NO893205D0 (no) 1989-08-09
ATE92485T1 (de) 1993-08-15
EP0354777A3 (fr) 1991-04-10
FI893751A (fi) 1990-02-11
KR900003151A (ko) 1990-03-23
EP0354777B1 (fr) 1993-08-04
FI893751A0 (fi) 1989-08-09
DK391289A (da) 1990-02-11

Similar Documents

Publication Publication Date Title
EP0354777B1 (fr) Dérivés du 3-(4-pipéridine)-5-(2-sulfonylaminoéthyl)-indole
US4997841A (en) Indole derivatives
US5066660A (en) Indole derivatives
US5475020A (en) Indolyl compounds and their use in treatment of cephalic pain
EP0147107B1 (fr) Derivés du noyau indole
IE55358B1 (en) Indoles
EP0330469A2 (fr) Dérivés de la tétrahydroisoquinoléine
US5013733A (en) Lactam derivatives
US4950681A (en) Ketone derivatives
US5116842A (en) Chemical compounds
EP0225726A1 (fr) Dérivés de l&#39;indole
US5026722A (en) Indole derivatives
US5001135A (en) Indole derivatives
US5494910A (en) Benzofuran derivatives as 5-HT1 -like receptor antagonists
US5008272A (en) Lactam derivatives
US4963546A (en) Ketone derivatives which are antagonists of 5-HT at 5-HT3 receptors, compositions containing them, and method of use
US5770611A (en) Indole derivatives as 5HT1 -like agonists
US5114950A (en) 5,6-dihydro-N-[(imidazol-4(or 5)-yl)methyl]-4H-pyrrolo[3,2,1-IJ]quinoline-1-carboxamides having 5-HT.sub. antagonist activity
EP0345956B1 (fr) Cétones tricycliques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19910724

17Q First examination report despatched

Effective date: 19911007

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

ITF It: translation for a ep patent filed
AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19930804

Ref country code: NL

Effective date: 19930804

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19930804

Ref country code: ES

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19930804

Ref country code: AT

Effective date: 19930804

REF Corresponds to:

Ref document number: 92485

Country of ref document: AT

Date of ref document: 19930815

Kind code of ref document: T

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19930831

REF Corresponds to:

Ref document number: 68908040

Country of ref document: DE

Date of ref document: 19930909

ET Fr: translation filed
NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20010730

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20010808

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20010810

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20010815

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20010927

Year of fee payment: 13

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020809

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020831

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020831

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020831

BERE Be: lapsed

Owner name: *GLAXO GROUP LTD

Effective date: 20020831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030301

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20020809

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030430

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050809